Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions

NCT03805841 is registered in ClinicalTrials.gov with Rain Oncology Inc as lead sponsor.

NCT NCT03805841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03805841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions
Lead sponsor
Rain Oncology Inc
Phase
Phase 2
Overall status
Terminated
Start date
March 13, 2019
Completion date
April 23, 2021
Enrollment
41 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

egfr exon 20 insertion mutation, erbb fusion, her2-activating mutation, nrg1 fusion, nsclc stage iiib, nsclc, recurrent, nsclc, stage iiic, nsclc, stage iv